Document Reference: AHQ-WEB-EDU-MBS-001 | Version 1.0 | July 2026
| Important Notice: Educational resource only. Not financial or medical advice. Patients should verify current Medicare and insurance coverage with their fund and treating practitioners. |
One of the most common questions asked by patients considering regenerative medicine in Australia is whether the treatment is covered by Medicare or private health insurance. The short answer is: not currently, for most cellular therapy procedures.
Medicare and the MBS
The Medicare Benefits Schedule (MBS) lists the medical services for which the Australian Government provides a rebate. For a service to be listed on the MBS, it must go through a formal assessment process by the Medical Services Advisory Committee (MSAC), which evaluates clinical evidence for safety, clinical effectiveness, and cost-effectiveness.
Autologous cellular therapies, including SVF therapy, are not currently listed on the MBS. This means there is no Medicare rebate available for these procedures. This does not reflect a safety determination — it reflects that the formal MSAC review process has not yet been completed for these procedures in the Australian context.
Private Health Insurance
Private health insurance coverage for cellular therapies varies between funds and depends on the specific procedure, the facility, and the policy held. Patients are encouraged to contact their fund directly to confirm whether any components of their treatment — including the day hospital admission — may attract a benefit under their policy.
What This Means for Patients
Regenerative medicine at Aeterna Health Queensland is accessed on a private-pay basis. The clinical team discusses costs transparently during the specialist consultation process. No financial commitment is required before that consultation takes place.
Leave a Reply